Announcements Trials
Browse Landscape

Phase

Phase NA 3Phase 4 1Phase 2/3 1Phase 2 1Phase 1/2 1Phase 1 1

Status

Unknown 1Terminated 1Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Advanced Solid Tumor 1

Interventions

Cyclophosphamide 118Specimen Handling 104pembrolizumab 103Magnetic Resonance Spectroscopy 95fludarabine 93Biopsy 77Injections 53Nivolumab 43Bevacizumab 41Fluorouracil 38venetoclax 37Cisplatin 37Paclitaxel 35Cetuximab 35Carboplatin 35Radiotherapy 31Oxaliplatin 30fludarabine phosphate 29Gemcitabine 29Leucovorin 28Drug Therapy 25Ipilimumab 23Immunotherapy, Adoptive 23Azacitidine 23Radiation 21Irinotecan 21Temozolomide 20130-nm albumin-bound paclitaxel 20tislelizumab 19atezolizumab 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Recruiting × Antineoplastic Agents × Clear all
NCT06625593 2026-05-29

A First-in-Human (FIH) Study of BG-C137, an Anti-Fibroblast Growth Factor Receptor 2b (FGFR2b) Antibody Drug Conjugate, in Participants With Advanced Solid Tumors

BeOne Medicines

Phase 1 Recruiting
168 enrolled
Other solid neoplasm

Advanced Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡